Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)
ANNALS OF ONCOLOGY（2016）
关键词
colorectal cancer,chemotherapy,third-line,wild-type,k-ras,first-line
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要